134 related articles for article (PubMed ID: 31997309)
1. Prediction of significant bleeding during vitamin K antagonist treatment for venous thromboembolism in outpatients.
Martinez C; Katholing A; Wallenhorst C; Cohen AT
Br J Haematol; 2020 May; 189(3):524-533. PubMed ID: 31997309
[TBL] [Abstract][Full Text] [Related]
2. A Novel Risk Prediction Score for Clinically Significant Bleeding in Patients Anticoagulated for Venous Thromboembolism with Active Cancer.
Cohen AT; Wallenhorst C; Choudhuri S; Nassar A; Pollock KG; Martinez C
Thromb Haemost; 2024 Apr; 124(4):324-336. PubMed ID: 37527782
[TBL] [Abstract][Full Text] [Related]
3. The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study.
Poli D; Antonucci E; Testa S; Cosmi B; Palareti G; Ageno W;
J Thromb Haemost; 2013 Jun; 11(6):1053-8. PubMed ID: 23578305
[TBL] [Abstract][Full Text] [Related]
4. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study.
Riva N; Bellesini M; Di Minno MN; Mumoli N; Pomero F; Franchini M; Fantoni C; Lupoli R; Brondi B; Borretta V; Bonfanti C; Ageno W; Dentali F
Thromb Haemost; 2014 Sep; 112(3):511-21. PubMed ID: 24899092
[TBL] [Abstract][Full Text] [Related]
5. Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials.
Wang W; Su Y; Wu C; Sun Y; Dai N; Chen W; Zhang J; Xu Y; Brindis RG; Xu D; Li J
BMC Cardiovasc Disord; 2020 Feb; 20(1):53. PubMed ID: 32013892
[TBL] [Abstract][Full Text] [Related]
6. Risk of recurrent venous thromboembolism after discontinuation of vitamin K antagonist treatment: a nested case-control study.
Martinez C; Katholing A; Folkerts K; Cohen AT
J Thromb Haemost; 2016 Jul; 14(7):1374-83. PubMed ID: 27079164
[TBL] [Abstract][Full Text] [Related]
7. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
Di Nisio M; Raskob G; Büller HR; Grosso MA; Zhang G; Winters SM; Cohen A
Thromb Haemost; 2017 Apr; 117(4):784-793. PubMed ID: 28151543
[TBL] [Abstract][Full Text] [Related]
8. Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism.
Leiss W; Méan M; Limacher A; Righini M; Jaeger K; Beer HJ; Osterwalder J; Frauchiger B; Matter CM; Kucher N; Angelillo-Scherrer A; Cornuz J; Banyai M; Lämmle B; Husmann M; Egloff M; Aschwanden M; Rodondi N; Aujesky D
J Gen Intern Med; 2015 Jan; 30(1):17-24. PubMed ID: 25143224
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
10. Decreased Bleeding Incidence with Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients with Sickle Cell Disease and Venous Thromboembolism.
Patel A; Williams H; Baer MR; Zimrin AB; Law JY
Acta Haematol; 2019; 142(4):233-238. PubMed ID: 31108496
[TBL] [Abstract][Full Text] [Related]
11. Management and outcome of major bleeding in patients receiving vitamin K antagonists for venous thromboembolism.
Moustafa F; Stehouwer A; Kamphuisen P; Sahuquillo JC; Sampériz Á; Alfonso M; Pace F; Suriñach JM; Blanco-Molina Á; Mismetti P; Monreal M;
Thromb Res; 2018 Nov; 171():74-80. PubMed ID: 30265883
[TBL] [Abstract][Full Text] [Related]
12. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review.
Wu C; Alotaibi GS; Alsaleh K; Sean McMurtry M
Thromb Res; 2014 Sep; 134(3):627-32. PubMed ID: 25047174
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis.
Bleker SM; Brekelmans MPA; Eerenberg ES; Cohen AT; Middeldorp S; Raskob G; Büller HR
Thromb Haemost; 2017 Oct; 117(10):1944-1951. PubMed ID: 28816341
[TBL] [Abstract][Full Text] [Related]
14. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
Andras A; Sala Tenna A; Stewart M
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002001. PubMed ID: 28737834
[TBL] [Abstract][Full Text] [Related]
15. Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism: comment.
Gaboreau Y; Zenatti N; Vermorel C; Imbert P; Bosson JL; Pernod G
J Thromb Thrombolysis; 2018 Jul; 46(1):84-87. PubMed ID: 29687300
[TBL] [Abstract][Full Text] [Related]
16. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
17. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism.
Chai-Adisaksopha C; Iorio A; Crowther MA; de Miguel J; Salgado E; Zdraveska M; Fernández-Capitán C; Nieto JA; Barillari G; Bertoletti L; Monreal M;
Am J Med; 2018 Apr; 131(4):430-437. PubMed ID: 29274307
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
Brekelmans MP; Bleker SM; Bauersachs R; Boda Z; Büller HR; Choi Y; Gallus A; Grosso MA; Middeldorp S; Oh D; Raskob G; Schwocho L; Cohen AT
Thromb Haemost; 2016 Jul; 116(1):155-61. PubMed ID: 27010092
[TBL] [Abstract][Full Text] [Related]
19. The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment.
Kooiman J; van Hagen N; Iglesias Del Sol A; Planken EV; Lip GY; van der Meer FJ; Cannegieter SC; Klok FA; Huisman MV
PLoS One; 2015; 10(4):e0122520. PubMed ID: 25905638
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
